Trials / NCT02781480
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
Completed Phase 1 / Phase 2 Gene therapy
- Sponsor
- MeiraGTx UK II Ltd
- Treatment
- AAV RPE65
- Gene
- RPE65
- Conditions
- Leber Congenital Amaurosis
- Ages
- 3 Years to no upper limit
- Enrollment
- 15 participants
- Started
- 2016-04
- Main results expected
- 2018-12
- Results posted
- Yes
- Record last updated
- 2021-07-12
What the study is testing
A clinical trial of AAV2/5 vector for patients with Defects in RPE65
Where it runs
United Kingdom (1)
- Moorfields Eye Hospital NHS Foundation Trust, London
United States (1)
- Kellogg Eye Centre, University of Michigan, Ann Arbor, Michigan